

23rd Annual Cancer Progress Conference

The Westin New York at Times Square

March 6-7, 2012

Program Agenda

Tuesday, March 6th 2012

Opening Remarks

Jeff Bockman, PhD, *Vice President, Defined Health*

Keynote Address: Point/Counterpoint on Angiogenesis

George D. Yancopoulos, MD, PhD

Executive Vice President, Chief Scientific Officer, and President, Regeneron Research Laboratories

Rakesh K. Jain, PhD*, *Massachusetts General Hospital*

The Future of Cancer Therapy: Where have we been, Where are we going?

Moderator: **Neal Rosen, MD**, *Professor of Medicine, Memorial Sloan-Kettering Cancer Center*

Panelists:

Steven Averbuch, MD

VP, Early Global Clinical Research Oncology & Head, Pharmacodiagnosics, Bristol-Myers Squibb

Larry Norton, MD

Deputy Physician-in-Chief for Breast Cancer Programs; Medical Director, Evelyn H. Lauder Breast Center & Norma S. Sarofim Chair in Clinical Oncology, Memorial Sloan-Kettering Cancer Center

Novel Approaches in Cancer Drug Development and Clinical Trials: Are we adapting and adopting fast enough?

Panelists:

Carlos Arteaga, MD

Associate Director for Clinical Research and Director Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center

Richard Gaynor, MD

VP, Cancer Research & Global Oncology Platform Leader, Eli Lilly and Company

Daniel Haber, MD*

Director, Mass General Hospital Cancer Center

Immunotherapy for Cancer: Are we there yet? The rights and wrongs of developing next generation immunotherapies

Panelists:

Jedd Wolchok, MD, PhD

Medical Oncologist, Memorial Sloan-Kettering Cancer Center

H. Kim Lyerly MD, FACS

George Barth Gellar Professor of Cancer Research, Professor of Surgery, Associate Professor of Pathology, Assistant Professor of Immunology, Duke University Comprehensive Cancer Center

Jon Wigginton, MD

Executive Medical Director, Co-Therapeutic Area Head, Discovery Medicine-Clinical Oncology, Bristol-Myers Squibb Company

Mary L. (Nora) Disis, MD

Associate Member, Fred Hutchinson Cancer Research Center, Professor, Division of Medical Oncology and Associate Dean of Translational Science, University of Washington School of Medicine

Steven A. Rosenberg, MD, PhD*

Chief of Surgery and Branch Chief, Tumor Immunology, National Cancer Institute; Professor of Surgery, Uniformed Services University of Health Sciences and George Washington University School of Medicine and Health Sciences

James P. Allison, PhD*

Chief of Immunology at the Sloan-Kettering Institute, Memorial Sloan Kettering Cancer Center, and Professor of Immunology, Gerstner Sloan-Kettering Graduate School of Biomedical Sciences

Apoptosis: Why has drug development in apoptosis been stymied?

Panelists:

Tak Mak, PhD

Director, The Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute; University Professor, University of Toronto

David Weng, MD, PhD

Chief Medical Officer, TetraLogic Pharmaceuticals, Inc.

John C. Reed, MD, Ph.D.

CEO, Professor and Donald Bren Chief Executive Chair, Apoptosis and Cell Death Research, Sanford-Burnham Medical Research Institute

Big Data: Data, data everywhere -- Generating, harvesting and analyzing the vast fields of cancer information

Moderator:

Colin Hill

Chief Executive Officer, President & Chairman, GNS Healthcare

Panelists

Eric E. Schadt, PhD

Chief Science Officer, Pacific Biosciences; Chair, Department of Genetics and Head, Institute for Genomics and Multiscale Biology Mt. Sinai Medical School

Felix W, Frueh, PhD*

VP Personalized Medicine R & D, Medco Health Solutions

Jay T. Flatley*

President and CEO, Illumina, Inc

Leroy Hood, MD*

President and Co-Founder, Institute for Systems Biology

Stephen Quake, PhD*

*Professor of Bioengineering & Co-Chair, Department of Bioengineering, Stanford University;
Investigator, Howard Hughes Medical Institute*

Melanoma: Tackling the intractable, but what next?

Panelists:

Jedd Wolchok, MD, PhD

Medical Oncologist, Memorial Sloan-Kettering Cancer Center

Paul Chapman, MD

Medical Oncologist, Memorial Sloan-Kettering Cancer Center

Lynda Chin, MD*

Chair, Genomic Medicine, University of Texas MD Anderson Cancer Center

Annual Reception and Szent-Györgyi Prize Awards Dinner

Sponsored by the National Foundation for Cancer Research

Wednesday, March 7th

Opening Remarks

Michael Rice, *Senior Consultant, Defined Health*

Keynote address: (Title TBA)

Kenneth C. Anderson, MD

Director, Clinical Research, LeBow Institute for Myeloma Therapeutics & Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute

Ovarian Cancer: Response followed by relapse, when will we shift the paradigm?

Panelists:

Laura K. Shawver, PhD

Founder, The Clarity Foundation

Robert C. Bast, Jr., MD

VP for Translational Research, University of Texas MD Anderson Cancer Center

Douglas A. Levine, MD

Head, Gynecology Research Laboratory, Associate Attending Surgeon, Gynecology Service/Dept. of Surgery, Memorial Sloan-Kettering Cancer Center

Robert Wasserman, MD*

Vice President, Head of Exploratory Development, Oncology, Roche

Michael Burgess, MB, ChB*

Senior Vice President, Oncology Research and Early Development, Roche

Novel MOAs and Targets for Cancer Drug Development: What's hot off the presses?

Moderator:

Jeremy Goldberg, *President, JPG Healthcare LLC*

Panelists:

Robert J Schneider, PhD

Albert B. Sabin Professor of Microbiology and Molecular Pathogenesis; NYU School of Medicine

Paul B. Fisher, MPh, PhD

Professor & Chairman, Institute of Molecular Medicine, Virginia Commonwealth University School of Medicine and Massey Cancer Center

Carlo M. Croce, MD

Professor of Internal Medicine; The John W. Wolfe Chair in Human Cancer Genetics; Director, Institute of Genetics; and Chair, Molecular Virology, Immunology, and Medical Genetics, Ohio State University Medical Center

Philip W. Kantoff, MD

Professor, Department of Medicine, Harvard Medical School; Physician, Brigham and Women's Hospital; Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute

ROI in Cancer: How successful has drug discovery and development been in cancer?

Moderator:

Mark J. Simon*, *Advisor, Torrey Partners LLC*

Panelists:

George S. Golumbeski, PhD

Vice President, Business Development, Celgene Corporation

Julio Gagne

Director of Portfolio & Asset Strategy - Oncology & Immunology, Bristol-Myers Squibb Company

Comparative Effectiveness and Reimbursement: Are we setting the bar sufficiently high from Proof of Concept to Proof of Relevance?

Panelists:

Debra Schrag, MD

Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute

Felix Frueh, PhD

Vice President, Research and Development, Personalized Medicine, Medco Health Solutions

Alex Kudrin, MD, PhD*

Medical Director in Gastroenterology, Immunology, Inflammation, and Vaccines, Takeda Pharmaceuticals Global R & D

Biomarkers, Companion Diagnostics and Enabling Technologies and Services for Personalized Medicine

Moderator:

Brian Leyland-Jones, MD, PhD

Professor of Medicine, Department of Medicine, Emory University

Panelists:

Carolyn Compton, MD, PhD

Director, Office of Biorepositories and Biospecimen Research, National Cancer Institute

Scott D. Patterson, PhD*

Executive Director, Medical Sciences, Amgen, Inc.

Steven Averbuch, MD

VP, Early Global Clinical Research Oncology & Head, Pharmacodiagnosics, Bristol-Myers Squibb

Robert Abraham, MD, PhD*

Vice President of Oncology, Pfizer

*Invited